Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Dow
AstraZeneca
Mallinckrodt
Express Scripts
Boehringer Ingelheim

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR ERTUGLIFLOZIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Ertugliflozin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00989079 ↗ A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036) Completed Pfizer Phase 1 2009-10-16 Ertugliflozin (PF-04971729, MK-8835) is a new compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this study is to evaluate the safety and tolerability along with the pharmacokinetics of single escalating doses of ertugliflozin under fed and fasted conditions in healthy volunteers.
NCT00989079 ↗ A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036) Completed Merck Sharp & Dohme Corp. Phase 1 2009-10-16 Ertugliflozin (PF-04971729, MK-8835) is a new compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this study is to evaluate the safety and tolerability along with the pharmacokinetics of single escalating doses of ertugliflozin under fed and fasted conditions in healthy volunteers.
NCT01018823 ↗ A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037) Completed Pfizer Phase 1 2009-12-14 Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2 Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of ertugliflozin.
NCT01018823 ↗ A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037) Completed Merck Sharp & Dohme Corp. Phase 1 2009-12-14 Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2 Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, of multiple oral doses of ertugliflozin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ertugliflozin

Condition Name

Condition Name for Ertugliflozin
Intervention Trials
Type 2 Diabetes Mellitus 16
Diabetes Mellitus, Type 2 6
Heart Failure With Reduced Ejection Fraction 2
Covid19 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ertugliflozin
Intervention Trials
Diabetes Mellitus, Type 2 24
Diabetes Mellitus 24
Heart Failure 7
Hypertension 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ertugliflozin

Trials by Country

Trials by Country for Ertugliflozin
Location Trials
United States 112
Russian Federation 9
Mexico 8
Ukraine 8
Hungary 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ertugliflozin
Location Trials
California 6
New York 5
Michigan 4
Illinois 4
Florida 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ertugliflozin

Clinical Trial Phase

Clinical Trial Phase for Ertugliflozin
Clinical Trial Phase Trials
Phase 4 8
Phase 3 14
Phase 2 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ertugliflozin
Clinical Trial Phase Trials
Completed 20
Recruiting 9
Not yet recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ertugliflozin

Sponsor Name

Sponsor Name for Ertugliflozin
Sponsor Trials
Merck Sharp & Dohme Corp. 27
Pfizer 21
University Health Network, Toronto 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ertugliflozin
Sponsor Trials
Industry 50
Other 29
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Baxter
McKesson
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.